PROTOCOLOS CLÍNICOS E DIRETRIZES TERAPÊUTICAS

Síndrome de Guillain-Barré Síndrome de Guillain-Barré a variant of the Guillain Barré syndrome. Arch Neurol. 1980;37(6):384-5. 29. Hughes RA, Swan AV, Raphael JC, Annane D, van Koningsveld R, van Doorn PA. Immunotherapy for Guillain-Barré syndrome: a systematic review. Brain. 2007;130(Pt 9):2245-57. Epub 2007 Mar 2. 30. Farcas P, Avnun L, Frisher S, Herishanu YO, Wirguin I. Efficacy of repeated intravenous immunoglobulin in severe unresponsive Guillain-Barré syndrome. Lancet. 1997;350(9093):1747. 31. Hughes RA, van der Meché FG. Corticosteroids for treating Guillain-Barré syndrome. Cochrane Database Syst Rev. 2000;(3):CD001446. 32. Hughes RA, Newsom-Davis JM, Perkins GD, Pierce JM. Controlled trial of prednisolone in acute polyneuropathy. Lancet. 1978;2(8093):750-3. 33. Doubleblind trial of intravenous methylprednisolone in Guillain-Barré syndrome Guillain-Barré Syndrome Steroid Trial Group. Lancet. 1993;341(8845):586-90. 34. Hughes RA, Kadlubowski M, Hufschmidt A. Treatment of acute inflammatory polyneuropathy. Ann Neurol.1981;9(Suppl):S125-33. 35. van Koningsveld R, Schmitz PI, Meché FG, Visser LH, Meulstee J, van Doorn PA, et al. Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain-Barre syndrome: randomised trial. Lancet. 2004;363(9404):192-6. 36. Brill V, Ilse WK, Pearce R, Dhanani A, Sutton D, Kong K. Pilot trial of immunoglobulin versus plasma exchange in patients with Guillain-Barré syndrome. Neurology. 1996;46(1):100-3. 37. Hughes RA, Raphaël JC, Swan AV, van Doorn PA. Intravenous immunoglobulin for Guillain-Barré syndrome. 2004;(1):CD002063. 38. Osterman PO, Fagius J, Lundemo G, Pihlstedt P, Pirskanen R, Sidén A, et al. Beneficial effects of plasma exchange in acute inflammatory polyradiculoneuropathy. Lancet. 1984;2(8415):1296-9. 39. Plasmapheresis and acute Guillain-Barré syndrome. The Guillain-Barré syndrome study group. Neurology. 1985;35(8):1096-104. 40. Efficiency of plasma exchange in Guillain-Barré syndrome: role of replacement fluids. French Cooperative Group on Plasma Exchange in Guillain-Barré syndrome. Ann Neurol.1987;22(6):753-61. 41. Apropriate number of plasma exchanges in Guillain-Barré syndrome. The French Cooperative Group on Plasma Exchange in Guillain-Barré syndrome. Ann of Neurol. 1997;41(3):287-8. 42. Plasma exchange in Guillain-Barré syndrome: one-year follow-up. French Cooperative Group on Plasma Exchange in Guillain-Barré syndrome. Ann Neurol. 1992;32(1):94-7.43. Zhang X, Xia J, Ye H. [Effect of tripterygium polyglycoside on interleukin-6 in patients with Guillain-Barré syndrome]. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2000;20(5):332-4. Chinese. 44. Wollinsky KH, Hülser PJ, Brinkmeier H, Aulkemeyer P, Bössenecker W, Huber-Hartmann KH, et al.CSF filtration is an effective treatment of Guillain-Barré syndrome: a randomized clinical trial. Neurology. 2001;57(5):774-80. 45. Bensa S, Hadden RD, Hahn A, Hughes RA, Willison HJ. Randomised controlled trial of brain-derived neurotrophic factor in Guillain-Barré syndrome: a pilot study. Eur J Neurol. 2000;7(4):423-6. 46. Pritchard J, Gray IA, Idrissova ZR, Lecky BR, Sutton IJ, Swan AV, et al. A randomized controlled trial of recombinant interferon-beta 1a in Guillain-Barré syndrome. Neurology. 2003;61(9):1282-4. 553